Two more biotechs are hoping to raise substantial funds for their R&D work while investors remain interested in the potential rewards of drug development.
So far this year 38 biotechs have gone public raising $2.8 billion.
Karyopharm Therapeutics, a clinical-stage pharmaceutical company, is focused on its lead anticancer contender, Selinexor. GlycoMimetics, has completed a mid-stage trial of its lead therapy, GMI-1070, which is aimed at rare cases of vaso-occlusive crisis triggered by sickle cell disease. Read more